Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 and AK112 in EGFR-mutant NSCLC
NCT05636267Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ambuzutinib and ivonescimab in non-small cell lung cancer (NSCLC), sponsored by Akeso, Inc. Primary endpoints: Number of subjects with dose limiting toxicities at 3 weeks, Number of subjects with adverse events and 1 more. Started Feb 2023; status: terminated.
02
Drugs
ambuzutinibivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05636267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636267.